ATE532792T1 - Künstliches cpg einzelstrang oligodeoxynukleotid und dessen antivirale anwendungen - Google Patents

Künstliches cpg einzelstrang oligodeoxynukleotid und dessen antivirale anwendungen

Info

Publication number
ATE532792T1
ATE532792T1 AT10174994T AT10174994T ATE532792T1 AT E532792 T1 ATE532792 T1 AT E532792T1 AT 10174994 T AT10174994 T AT 10174994T AT 10174994 T AT10174994 T AT 10174994T AT E532792 T1 ATE532792 T1 AT E532792T1
Authority
AT
Austria
Prior art keywords
virus
odns
stranded
cpg
artificial
Prior art date
Application number
AT10174994T
Other languages
English (en)
Inventor
Yongli Yu
Liying Wang
Original Assignee
Changchun Huapu Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN 03146157 external-priority patent/CN1289520C/zh
Priority claimed from CNB031562248A external-priority patent/CN1304412C/zh
Application filed by Changchun Huapu Biotechnology Co Ltd filed Critical Changchun Huapu Biotechnology Co Ltd
Application granted granted Critical
Publication of ATE532792T1 publication Critical patent/ATE532792T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT10174994T 2003-07-25 2004-07-26 Künstliches cpg einzelstrang oligodeoxynukleotid und dessen antivirale anwendungen ATE532792T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN 03146157 CN1289520C (zh) 2003-07-25 2003-07-25 具有抗流感病毒的含CpG单链脱氧寡核苷酸
CNB031562248A CN1304412C (zh) 2003-09-05 2003-09-05 抗单股正链RNA病毒人工合成的含CpG单链脱氧寡核苷酸

Publications (1)

Publication Number Publication Date
ATE532792T1 true ATE532792T1 (de) 2011-11-15

Family

ID=34137222

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04762006T ATE502949T1 (de) 2003-07-25 2004-07-26 Das künstliche cpg single strand deoxidation- oligonukleotid und dessen antivirale anwendungen
AT10174994T ATE532792T1 (de) 2003-07-25 2004-07-26 Künstliches cpg einzelstrang oligodeoxynukleotid und dessen antivirale anwendungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04762006T ATE502949T1 (de) 2003-07-25 2004-07-26 Das künstliche cpg single strand deoxidation- oligonukleotid und dessen antivirale anwendungen

Country Status (8)

Country Link
US (1) US7491706B2 (de)
EP (2) EP1650218B1 (de)
JP (1) JP4809220B2 (de)
KR (1) KR101146203B1 (de)
AT (2) ATE502949T1 (de)
CA (1) CA2533434C (de)
DE (1) DE602004031946D1 (de)
WO (1) WO2005014611A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006056142A1 (fr) * 2004-11-29 2006-06-01 Changchun Huapu Biotechnology Co., Ltd. Desoxynucleotides cpg a brin unique a utiliser comme adjuvant
CN1865275B (zh) 2005-05-17 2011-06-15 长春华普生物技术有限公司 对人b细胞肿瘤有治疗作用的人工合成的单链脱氧核苷酸
JP5759445B2 (ja) 2009-03-25 2015-08-05 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 病原体に対する哺乳類先天性免疫抵抗性の刺激のための組成物
KR101452830B1 (ko) * 2012-04-06 2014-10-21 아이진 주식회사 두 가지 항암물질을 동시에 제공하는 대장균 균주
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999051259A2 (en) * 1998-04-03 1999-10-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6977245B2 (en) * 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
CN1280303C (zh) * 2003-05-28 2006-10-18 长春华普生物技术有限公司 人工合成的含CpG单链脱氧寡核苷酸及其抗SARS病毒作用

Also Published As

Publication number Publication date
US20070155683A1 (en) 2007-07-05
EP2264046A1 (de) 2010-12-22
EP1650218A4 (de) 2008-07-02
EP1650218A1 (de) 2006-04-26
ATE502949T1 (de) 2011-04-15
CA2533434A1 (en) 2005-02-17
EP2264046B1 (de) 2011-11-09
US7491706B2 (en) 2009-02-17
JP2006528491A (ja) 2006-12-21
DE602004031946D1 (de) 2011-05-05
KR20060054354A (ko) 2006-05-22
EP1650218B1 (de) 2011-03-23
CA2533434C (en) 2011-07-05
KR101146203B1 (ko) 2012-05-25
JP4809220B2 (ja) 2011-11-09
WO2005014611A1 (fr) 2005-02-17

Similar Documents

Publication Publication Date Title
FR21C1037I1 (fr) Clades de virus adéno associés (aav), séquences, vecteurs les contenant et leurs utilisations
WO2003070193A3 (en) RNA interference mediated inhibition of HIV gene expression using short interfering nucleic acid (siNA)
DK3222722T3 (da) Antisense-design
SI2287305T2 (en) WITH RNA-INTERFERENCO-DELIVERED INHIBITION OF GEN expression by the use of a small interfering nucleic acid (SIN)
WO2006121464A3 (en) Compositions for treating respiratory viral infections and their use
WO2004039829A3 (en) Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
EP2284268A3 (de) Konservierte HBV- und HCV-Sequenzen zur Genausschaltung
ATE373671T1 (de) Aminooxy-modifizierte oligonukleotide
CA2457528A1 (en) Rna interference mediated inhibition of hepatitis c virus (hcv) gene expression using short interfering nucleic acid (sina)
WO2006047842A3 (en) Modified nucleosides for rna interference
DE69403642T2 (de) 7-deazapurin modifizierte oligonukleotide
CY1108870T1 (el) Αντιπαραλληλα ολιγονουκλεοτιδια (odn) κατα της smad7 και χρησεις στον ιατρικο τομεα τους
DE602004030583D1 (de) Oligonukleotidanalog und verfahren zur behandlung von flavivirusinfektionen
ATE346918T1 (de) Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide
ATE532792T1 (de) Künstliches cpg einzelstrang oligodeoxynukleotid und dessen antivirale anwendungen
IL153388A0 (en) Manipulation of negative stranded rna viruses by rearrangement of their genes and uses thereof
BRPI9800337A (pt) par de iniciadores de oligonucleotídeos para a amplificação de ácido nucléico de tipo 1 (hiv-1) de vírus de imunodeficiência humana, conjunto de iniciadores, kits para detectar o dito ácido nucléico, bem como processo para referida amplificação.
WO2004078941A3 (en) Modulation of gene expression using dna-rna hybrids
ATE281179T1 (de) Zusammensetzungen zur behandlung von viralen infektionen und verfahren dafür
DE60110244D1 (de) Chimerische antisense-oligonukleotide aus arabinofuranose-analogen und deoxyribose-nukleotide
DE60213406D1 (de) Pharmakologische anwendungen von mitochondriellen dna assays
WO2003031459A3 (de) Modulation der expression stat-1-abhängiger gene
WO2004035758A3 (en) Rna-based inhibitory oligonucleotides
PT1254663E (pt) Agente antiviral
DE60035680D1 (de) Komplette gensequenz des esel-leukozyten-impfstoffstammes des equinen infektiösen anemievirus und ihre anwendung